Abstract
The effectiveness of pharmacotherapy of acute infectious rhinitis in children by means of drugs from the list of medicines of the J00 Standard and in addition to this pharmacotherapy with the drug silver proteinate – 200 mg nasal spray Sialor® (manufacturer of JSC «Production Pharmaceutical Company “Obnovlenie”, Russia) was evaluated in a multicenter randomized comparative study. A higher quality of treatment was demonstrated when using 200 mg silver proteinate (Sialor®) in the form of a nasal spray in complex therapy. The article presents evidence of the feasibility of including the drug 200 mg silver proteinate in the list of medicines of the J00 Standard.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
